Our team has a wealth of experience and expertise in the development of protein/peptide therapeutics and an in-depth understanding of the needs of the pharmaceutical industry when it comes to the development and manufacture of novel, effective and safe biologics. In addition, with our business acumen and experience of forming strategic alliances we are working to build effective partnerships to deliver biologics solutions:
Dr Mike Owen | Non-Exec Director
Dr Owen was Senior Vice President and global Head of Research of the Biopharmaceuticals R&D Unit at GlaxoSmithKline and was responsible for initiating and rapidly growing GSK's robust pre-clinical and clinical therapeutic antibody pipeline during the last decade through in-house development as well as through acquisitions such as Domantis. He left GSK in 2010 to establish Kymab which is developing biotherapeutics using its novel transgenic mouse platform. Dr Owen is an immunologist by training who had a highly successful scientific career at the Imperial Cancer Research Fund during which he was elected a member of the European Molecular Biology Organisation and a fellow of the Academy of Medical Sciences. Dr Owen is also an independent board member at Zealand Pharma and non-executive director of ReNeuron plc, Avacta Group plc, GammaDelta Therapeutics, Ossianix Inc. and Blink Therapeutics. He also advises the private equity CRT Pioneer Fund and Abingworth LLP.